Trial reportCancer communications (London, England)2018
Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Trial report in Cancer communications (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Bibliometric analysis of preoperative radiotherapy for locally advanced rectal cancer: evolution and future.Frontiers in medicine · 2025Pooled it
- A multicohort, biomarker-driven phase 2 trial of personalized total neoadjuvant therapy with targeted agents for high-risk rectal cancer (The TRAINER study).Signal transduction and targeted therapy · 2026Trial
- Local and symptomatic control evaluation in palliative radiotherapy for rectal adenocarcinoma in frail, elderly, or metastatic patients: a multicentric retrospective study.Clinical and translational radiation oncology · 2026Article
- Optimizing total neoadjuvant therapy in locally advanced rectal cancer: risk stratification should not be overlooked.Future oncology (London, England) · 2025Review
- Impact of Subcutaneous Adipose Tissue Index Change During Neoadjuvant Chemoradiotherapy on Disease-Free Survival and Tumor Response in Patients with Locally Advanced Rectal Cancer.International journal of medical sciences · 2025Article
- Short-term and long-term oncological outcomes of chemoradiotherapy for rectal cancer patients with or without oxaliplatin: a propensity score-matched retrospective analysis.Radiation oncology (London, England) · 2024Article
- Case report: A clinical report of photodynamic neoadjuvant combined with fluorescent laparoscopic localization robotic surgery for the treatment of patients with advanced colorectal cancer combined with obstruction.Frontiers in immunology · 2024Article
- Role of Oxaliplatin in the Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: a Review of Evidence.Clinical Medicine Insights. Oncology · 2024Review
- Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma.Frontiers in oncology · 2023Article
- Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer.Frontiers in oncology · 2023Review
- Article
- High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer.Radiation oncology (London, England) · 2022Article
- Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.Cell communication and signaling : CCS · 2022Review
- XRCC2 reduced the sensitivity of NSCLC to radio-chemotherapy by arresting the cell cycle.American journal of translational research · 2022Article
- Article
- Gastrointestinal Perforation With an Intraluminal Stent and Bevacizumab use in Advanced Metastatic Colorectal Cancer.Cureus · 2021Article
- Effects of bevacizumab combined with oxaliplatin intrathoracic injection on tumor markers and survival rate in patients with malignant pleural effusion of lung cancer.American journal of translational research · 2021Article
- Clinical Effect of Radiotherapy Combined with Capecitabine after Neoadjuvant Therapy for Rectal Cancer.Journal of oncology · 2021Article
- The efficacy and safety of adding bevacizumab in neoadjuvant therapy for locally advanced rectal cancer patients: A systematic review and meta-analysis.Translational oncology · 2021Article
- Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review.Radiation oncology (London, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemoradiotherapy followed by surgery is recommended as the standard of care for locally advanced rectal cancer, reducing local recurrence but not distant metastasis. Intensified systemic therapy is warranted to reduce the risk of distant metastasis. The present study aimed to evaluate the safety and efficacy of neoadjuvant oxaliplatin and capecitabine (XELOX) combined with bevacizumab plus radiotherapy for locally advanced rectal cancer.
methodsPatients with stages II to III rectal cancer received one cycle of induction chemotherapy and concurrent chemoradiotherapy with XELOX plus bevacizumab. Surgery was performed 6-8 weeks after completion of radiotherapy, and postoperative chemotherapy with three cycles of XELOX and two cycles of capecitabine were given. The primary endpoints were pathologic complete response (pCR) rate and safety, and the secondary endpoints were 3-year overall survival and progression-free survival.
resultsForty-five patients were enrolled between February 2013 and April 2015. All completed the neoadjuvant therapy. Seven patients (15.6%) refused subsequent surgical therapy for personal reasons, and the other 38 patients received radical resection, with a sphincter preservation rate of 84.2% and a pCR rate of 39.5%. Toxicity was acceptable, with grades 3-4 hematological toxicity and diarrhea observed in six and two patients, respectively. Incidence of anastomotic leak that required surgical intervention was 13.3%. After a median follow-up period of 37 months, five patients developed disease progression and two died of cancer. The 3-year overall survival rate and 3-year progression-free survival rate were 95.3% and 88.6%, respectively.
conclusionsThe addition of bevacizumab to neoadjuvant chemoradiotherapy resulted in a satisfying pCR rate and 3-year survival, but also may increase the risk of anastomotic leak, thus this regimen is not suitable to be considered for regular recommendation for locally advanced rectal cancer. Trial registration Clinicaltrials.govidentifierNCT01818973.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.